LBF20406PH01: Difference between revisions
No edit summary |
No edit summary |
||
| (13 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR7016 | |LipidBank=XPR7016 | ||
|LipidMaps=LMFA08020002 | |LipidMaps=LMFA08020002 | ||
|SysName= | |SysName=N- (cis-5,cis-8,cis-11,cis-14) -Tetraenoyleicosaethanolamine-O-phosphate | ||
|Common Name=&& | |Common Name=&&Anandamide 0-phosphate&&N- (5Z,8Z,11Z,14Z) -Tetraenoyleicosaethanolamine-O-phosphate&& | ||
|Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | ||
|NMR Spectra= | |NMR Spectra=^1 H NMR (CDCl3) delta 5.34-5.42 (m, 8H), 3.98 (br s 2H), 3.46 (br s 2H), 2.77-2.81 (m, 6H), 2.26 (t, J=6.8Hz, 2H), 2.00-2.06 (m, 4H), 1.60-1.69 (m, 2H), 1.29-1.42 (m, 6H), 0.88 (t, J=6.9Hz,3H) [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | ||
|Source= | |||
|Chemical Synthesis=This compound was synthesized from N-hydroxysuccinimide ester of arachidonic acid and O-phosphoethanolamine in 60% yield. [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |||
|Metabolism= | |||
|Biological Activity=Binding of this compound to the brain cannabinoid receptor (CBl),Ki(nM)= 190.8±11.1[[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 08:26, 29 September 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR7016 |
| LipidMaps | LMFA08020002 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20406PH01 |
| Anandamide 0-phosphate | |
|---|---|
| |
| Structural Information | |
| N- (cis-5,cis-8,cis-11,cis-14) -Tetraenoyleicosaethanolamine-O-phosphate | |
| |
| Formula | C22H38NO5P |
| Exact Mass | 427.2487598409999 |
| Average Mass | 427.51462100000003 |
| SMILES | C(CCCC=CCC=CCC=CCC=CCCCCC)(NCCOP(O)(O)=O)=O |
| Physicochemical Information | |
| colorless oil Sheskin_T et al. | |
| This compound was synthesized from N-hydroxysuccinimide ester of arachidonic acid and O-phosphoethanolamine in 60% yield. Sheskin_T et al. | |
| Binding of this compound to the brain cannabinoid receptor (CBl),Ki(nM)= 190.8±11.1 Sheskin_T et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | 1H NMR (CDCl3) δ 5.34-5.42 (m, 8H), 3.98 (br s 2H), 3.46 (br s 2H), 2.77-2.81 (m, 6H), 2.26 (t, J=6.8Hz, 2H), 2.00-2.06 (m, 4H), 1.60-1.69 (m, 2H), 1.29-1.42 (m, 6H), 0.88 (t, J=6.9Hz,3H) SheskinTet al. |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
